Back to search

Peptide record

TPDB03209

PTP1 Antibacterial Anticancer Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB03209
PTP1
Antibacterial Anticancer Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP Peptipedia AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, and Toxicity) peptide sequence curated from AntiBP3, dbAMP, Peptipedia, and other sources, with an available 3D structural model.
Sequence
LLAGLAANFLPTIICKISYKC
Physicochemical Analysis
C105H174N24O26S2
RDEQHMWV
L
2252.80
9.03
2
0
12
+2
-3.10
1.229
144.29
Mammalian: 5.5 hour Yeast: 3 min E.coli: 2 min
1615
71.69
6
Residue Composition
number
3
A
0
R
1
N
0
D
2
C
0
E
0
Q
1
G
0
H
3
I
4
L
2
K
0
M
1
F
1
P
1
S
1
T
0
W
1
Y
0
V
Amino Acid Distribution
A: 3 R: 0 N: 1 D: 0 C: 2 E: 0 Q: 0 G: 1 H: 0 I: 3 L: 4 K: 2 M: 0 F: 1 P: 1 S: 1 T: 1 W: 0 Y: 1 V: 0
Chemical Descriptors
21
C105H174N24O26S2
2252.80
9.03
+2
-3.10
1.229
Free
L
Cyclic(C15-C21)
Free
Antibacterial
Gaegurin
Evidence Records 6 records
Evidence 1 Activity

Activity

IC50
IC50= >100 µg/ml
Anticancer
>100 µg/mL

Target

Lung Cancer
A-549
Lung

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 2 Activity

Activity

IC50
IC50=>100 µg/ml
Anticancer
>100 µg/mL

Target

Renal Cancer
293
Renal

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 3 Activity

Activity

IC50
IC50=>100 µg/ml
Anticancer
>100 µg/mL

Target

Liver Cancer
Hep3B
Liver

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 4 Activity

Activity

IC50
IC50=>100 µg/ml
Anticancer
>100 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
96-h

Source & Reference

CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2003
Evidence 5 Activity

Activity

IC50
Toxicity
>100 µg/mL
Cytotoxic
IC50 | >100 | µg/mL | target cell: Human embryonic kidney HEK293T cells

Target

Human embryonic kidney HEK293T cells

Source & Reference

NA
DBAASP
In vitro activities of native and designed peptide antibiotics against drug sensitive and resistant tumor cell lines. | Peptides | 2003
Evidence 6 Activity

Activity

IC50
Toxicity
100 µg/mL
Hemolytic Cytotoxic
Hemolytic_activity: Human RBCs: less than 6% hemolysis at 100 µg/ml | Cytotoxicity: HEK293: IC50>100 µg/ml

Target

erythrocytes

Source & Reference

NA
DRAMP
Peptides. 2003 Jul 24(7):945-53.